الفهرس | Only 14 pages are availabe for public view |
Abstract Breast cancer is the most common cancer worldwide for females, and the 2nd most common cancer overall (Ferlay et al., 2013). miRNAs may be exploited as a new kind of molecular markers for follow up of breast cancer (Zeng et al., 2014). This study was carried out at medical biochemistry Department, in collaboration with General surgery Department, Faculty of Medicine, Ain Shams University, and was approved by the research ethical committee of Faculty of Medicine, Ain Shams University during the years (2013-2014). The study included 58 female. Participants were classified into two groups. Group A, consisted of thirty eight females with histopathologicaly confirmed malignant breast tumors. Breast cancer patients underwent either breast conserving surgery or modified radical mastectomy. Patients who had received any chemotherapy or radiation therapy before surgery or who had rheumatic disease, acute infection, or other types of cancer were excluded from the current study. Clinical staging of breast cancer was performed according to TNM classification (AJCC, 2010). Summary, Conclusion & Recommendation 132 Group B, consisted of twenty females who underwent breast reduction as a control group. They were recruited from plastic surgery department, Faculty of medicine, Ain shams university. The aim of the present study was to investigate the synergistic expression of miR-96 and miR-155 in breast cancer and to evaluate their efficacy as potential prognostic markers using quantitative real-time PCR. Quantitative real-time PCR is considered as the gold standard for measuring of miRNAs levels (Schmittgen et al., 2008). Our results revealed the following: The expression level of each of miRNA (96 and 155) was significantly higher in breast cancer than normal control tissues. The sensitivity of miR-96 expression in breast cancer tissue was significantly higher (86.8%) than miR-155 (78.9%). Meanwhile, the specificity of each of them was the same (95%). The expression of miR-96 and miR-155 was significantly higher in advanced stage and lymph node metastasis in breast cancer group. Summary, Conclusion & Recommendation 133 The high expression of miR-155 in premenopausal patients with breast cancer may give better understanding about the mechanism of the currently used antiestrogen therapy. On combining miR-96 and miR-155, the sensitivity was increased to reach 92.1% whereas, the specificity remained the same. Expression of miR-96 could be influenced by miR-155 expression as shown in 93.3% of breast cancer tissues included in our study. These current findings could propose the idea that analysis of combined expression of miR-96 and miR-155 may be of prognostic value in breast cancer. Recommendations It would be interesting to analyze the expression profile of these two miRNAs together in serum, (or plasma) of breast cancer patients looking for a non invasive diagnostic tool. Further research concerning the potential use of miR- 96 and miR-155 as therapeutic targets in breast cancer treatment is urgently needed |